Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow Quality Index
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow Quality Index of 17.57x as of September 2025. Operating cash flow of ₩6.82 Billion exceeds net income of ₩388.45 Million, indicating high earnings quality where cash backs reported profits. Explore 061250 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hwail Pharmaceutical Co.Ltd Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for Hwail Pharmaceutical Co.Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 061250 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year earnings quality comparison for Hwail Pharmaceutical Co.Ltd. For live market cap and the full company financial profile, see market cap of Hwail Pharmaceutical Co.Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.80x | ₩11.63 Billion | ₩6.48 Billion | ▼ -1.3% |
| 2023 | 1.82x | ₩7.02 Billion | ₩3.86 Billion | ▼ -74.3% |
| 2021 | 7.07x | ₩20.09 Billion | ₩2.84 Billion | ▲ +9934.7% |
| 2020 | -0.07x | ₩-201.69 Million | ₩2.81 Billion | ▼ -106.2% |
| 2019 | 1.16x | ₩3.69 Billion | ₩3.19 Billion | ▼ -18.1% |
| 2018 | 1.41x | ₩7.17 Billion | ₩5.08 Billion | ▼ -54.9% |
| 2017 | 3.13x | ₩8.34 Billion | ₩2.67 Billion | ▲ +108.3% |
| 2016 | 1.50x | ₩9.58 Billion | ₩6.38 Billion | ▲ +218.6% |
| 2015 | -1.27x | ₩-6.90 Billion | ₩5.45 Billion | ▼ -87.9% |
| 2014 | -0.67x | ₩-2.78 Billion | ₩4.13 Billion | ▼ -140.7% |
| 2013 | 1.66x | ₩6.97 Billion | ₩4.21 Billion | ▲ +734.1% |
| 2012 | 0.20x | ₩1.00 Billion | ₩5.06 Billion | ▼ -88.2% |
| 2011 | 1.68x | ₩7.86 Billion | ₩4.69 Billion | — |